Chronic Lymphocytic Leukemia — Proceedings from a Symposium Held in Partnership with the American Oncology Network
Hematologic Oncology Update
00:00
Selecting frontline therapy by IGHV and comorbidity
Rogers explains preferring fixed‑duration venetoclax combos for IGHV‑mutated CLL, considering comorbidities and insurance effects.
Play episode from 15:44
Transcript
